The Role of Chemotherapy in Upper Tract Urothelial Carcinoma

por O'Donnell, Peter H., Stadler, Walter M.
Publicado 2009

Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures

por Lussier, Yves A, Stadler, Walter M, Chen, James L
Publicado 2011

Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence

por Chen, James L, Li, Jianrong, Stadler, Walter M, Lussier, Yves A
Publicado 2011

Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy

por Labbate, Craig, Hatogai, Ken, Werntz, Ryan, Stadler, Walter M., Steinberg, Gary D., Eggener, Scott, Sweis, Randy F.
Publicado 2019

Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report

por Hines, Jacobi, Daily, Ellen, Pham, Anh Khoa, Shea, Christopher R., Nadeem, Urooba, Husain, Aliya N., Stadler, Walter M., Reid, Pankti
Publicado 2021

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

por Chen, James L, Appelbaum, Daniel E, Kocherginsky, Masha, Cowey, Charles L, Kimryn Rathmell, Wendy, McDermott, David F, Stadler, Walter M
Publicado 2013

Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prosta...

por Reyes, Edwin E, VanderWeele, David J, Isikbay, Masis, Duggan, Ryan, Campanile, Alexa, Stadler, Walter M, Vander Griend, Donald J, Szmulewitz, Russell Z
Publicado 2014

Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase‐Associated Lipocalin and Cystatin C

por Jelinek, Michael J., Lee, Sang Mee, Wyche Okpareke, Alicia, Wing, Claudia, Koyner, Jay L., Murray, Patrick T., Stadler, Walter M., O’ Donnell, Peter H.
Publicado 2018

A randomized phase II study of pazopanib in hormone sensitive prostate cancer: a University of Chicago Phase II Consortium/ Department of Defense Prostate Cancer Clinical Trials Co...

por Ward, James E., Karrison, Theodore, Chatta, Gurkamal, Hussain, Maha, Shevrin, Daniel, Szmulewitz, Russell Z., O’Donnell, Peter H., Stadler, Walter M., Posadas, Edwin M.
Publicado 2011

Low-grade prostate cancer diverges early from high grade and metastatic disease

por VanderWeele, David J, Brown, Christopher D, Taxy, Jerome B, Gillard, Marc, Hatcher, David M, Tom, Westin R, Stadler, Walter M, White, Kevin P
Publicado 2014

Estimation of renal cell carcinoma treatment effects from disease progression modeling

por Maitland, Michael L., Wu, Kehua, Sharma, Manish R., Jin, Yuyan, Kang, Soonmo Peter, Stadler, Walter M., Karrison, Theodore G., Ratain, Mark J., Bies, Robert R.
Publicado 2012

EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells

por Sagar, Vinay, Vatapalli, Rajita, Lysy, Barbara, Pamarthy, Sahithi, Anker, Jonathan F., Rodriguez, Yara, Han, Huiying, Unno, Kenji, Stadler, Walter M., Catalona, William J., Hussain, Maha, Gill, Parkash S., Abdulkadir, Sarki A.
Publicado 2019

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

por Monk, Paul, Liu, Glenn, Stadler, Walter M., Geyer, Susan, Huang, Ying, Wright, John, Villalona-Calero, Miguel, Wade, James, Szmulewitz, Russell, Gupta, Shilpa, Mortazavi, Amir, Dreicer, Robert, Pili, Roberto, Dawson, Nancy, George, Saby, Garcia, Jorge A.
Publicado 2018

Samarium-153-EDTMP (Quadramet(®)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial

por Heery, Christopher R., Madan, Ravi A., Stein, Mark N., Stadler, Walter M., Di Paola, Robert S., Rauckhorst, Myrna, Steinberg, Seth M., Marté, Jennifer L., Chen, Clara C., Grenga, Italia, Donahue, Renee N., Jochems, Caroline, Dahut, William L., Schlom, Jeffrey, Gulley, James L.
Publicado 2016

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab

por Sznol, Mario, Fishman, Mayer, Escudier, Bernard, McDermott, David F, Kluger, Harriet, Stadler, Walter M, Perez-Gracia, Jose, McNeel, Douglas G, Curti, Brendan D, Harrison, Michael R, Plimack, Elizabeth R, Appleman, Leonard, Fong, Lawrence, Drake, Charles G, Young, Tina C, Chasalow, Scott D, Ross-MacDonald, Petra, Simon, Jason S, Walker, Dana, Choueiri, Toni K
Publicado 2015

Patient-Provider Communications About Pharmacogenomic Results Increase Patient Recall of Medication Changes

por Borden, Brittany A., Lee, Sang Mee, Danahey, Keith, Galecki, Paige, Patrick-Miller, Linda, Siegler, Mark, Sorrentino, Matthew J., Sacro, Yasmin, Davis, Andrew M., Rubin, David T., Lipstreuer, Kristen, Polonsky, Tamar S., Nanda, Rita, Harper, William R., Koyner, Jay L., Burnet, Deborah L., Stadler, Walter M., Kavitt, Robert T., Meltzer, David O., Ratain, Mark J., O’Donnell, Peter H.
Publicado 2019

Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics

por Meier, Jason P., Zhang, Hannah J., Freifelder, Richard, Bhuiyan, Mohammed, Selman, Phillip, Mendez, Megan, Kankanamalage, Pavithra H. A., Brossard, Thomas, Pusateri, Antonino, Tsai, Hsiu-Ming, Leoni, Lara, Penano, Sagada, Ghosh, Kaustab, Broder, Brittany A., Markiewicz, Erica, Renne, Amy, Stadler, Walter, Weichselbaum, Ralph, Nolen, Jerry, Kao, Chien-Min, Chitneni, Satish K., Rotsch, David A., Szmulewitz, Russell Z., Chen, Chin-Tu
Publicado 2023

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

por Catenacci, Daniel V.T., Junttila, Melissa R., Karrison, Theodore, Bahary, Nathan, Horiba, Margit N., Nattam, Sreenivasa R., Marsh, Robert, Wallace, James, Kozloff, Mark, Rajdev, Lakshmi, Cohen, Deirdre, Wade, James, Sleckman, Bethany, Lenz, Heinz-Josef, Stiff, Patrick, Kumar, Pankaj, Xu, Peng, Henderson, Les, Takebe, Naoko, Salgia, Ravi, Wang, Xi, Stadler, Walter M., de Sauvage, Frederic J., Kindler, Hedy L.
Publicado 2015

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

por Costello, Brian A., Bhavsar, Nrupen A., Zakharia, Yousef, Pal, Sumanta K., Vaishampayan, Ulka, Jim, Heather, Fishman, Mayer N., Molina, Ana M., Kyriakopoulos, Christos E., Tsao, Che-Kai, Appleman, Leonard J., Gartrell, Benjamin A., Hussain, Arif, Stadler, Walter M., Agarwal, Neeraj, Pachynski, Russell K., Hutson, Thomas E., Hammers, Hans J., Ryan, Christopher W., Mardekian, Jack, Borham, Azah, George, Daniel J., Harrison, Michael R.
Publicado 2022

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)

por Harrison, Michael R., Costello, Brian A., Bhavsar, Nrupen A., Vaishampayan, Ulka, Pal, Sumanta K., Zakharia, Yousef, Jim, Heather S. L., Fishman, Mayer N., Molina, Ana M., Kyriakopoulos, Christos E., Tsao, Che‐Kai, Appleman, Leonard J., Gartrell, Benjamin A., Hussain, Arif, Stadler, Walter M., Agarwal, Neeraj, Pachynski, Russell K., Hutson, Thomas E., Hammers, Hans J., Ryan, Christopher W., Inman, Brant A., Mardekian, Jack, Borham, Azah, George, Daniel J.
Publicado 2021